Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Events:

Patient Centricity and Engagement Conference 2021

Webcast:

UX beyond the website: Insights for the age of omnichannel

News:

MedTech Qualitative Specialist joins Research Partnership

Guide

How to embrace behavioural science principles in healthcare MR

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

‘Smear Word’ campaign for Roche aims to break taboos and save lives

An all-female team at Mind+Matter has created a campaign for Roche that takes a tongue-in-cheek approach to tackle taboos about going for a smear test.

Video

Virtual Conference Live

Report

Digital Health Tools - Physician Trends

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan